Avalon GloboCare (ALBT) Competitors $2.35 -0.07 (-2.89%) Closing price 04:00 PM EasternExtended Trading$2.22 -0.13 (-5.32%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. MIRA, NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, and QTTBShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors MIRA Pharmaceuticals Natural Alternatives International Briacell Therap Longeveron JATT Acquisition BioLineRx Cingulate Marker Therapeutics BioVie Q32 Bio MIRA Pharmaceuticals (NASDAQ:MIRA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Does the media favor MIRA or ALBT? In the previous week, Avalon GloboCare had 4 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Avalon GloboCare and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.96 beat Avalon GloboCare's score of 0.82 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment MIRA Pharmaceuticals Positive Avalon GloboCare Positive Which has higher valuation & earnings, MIRA or ALBT? MIRA Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-3.96Avalon GloboCare$1.37M3.25-$7.90M-$19.96-0.12 Is MIRA or ALBT more profitable? MIRA Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -341.08% -272.93% Avalon GloboCare -647.29%N/A -50.13% Which has more risk and volatility, MIRA or ALBT? MIRA Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Do insiders & institutionals believe in MIRA or ALBT? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend MIRA or ALBT? MIRA Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 593.07%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe MIRA Pharmaceuticals is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMIRA Pharmaceuticals beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.45M$2.93B$5.50B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.1220.3128.1019.86Price / Sales3.25261.57402.2879.25Price / CashN/A42.3835.5357.53Price / Book-0.217.838.265.72Net Income-$7.90M-$55.11M$3.24B$257.80M7 Day Performance-9.27%2.18%0.50%1.06%1 Month Performance-22.44%12.98%7.99%11.30%1 Year Performance-67.96%1.98%28.68%17.00% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.3598 of 5 stars$2.35-2.9%N/A-65.0%$4.45M$1.37M-0.125Gap DownMIRAMIRA Pharmaceuticals2.457 of 5 stars$1.15-4.2%$14.00+1,117.4%+130.9%$20.30MN/A-2.252NAIINatural Alternatives International1.4826 of 5 stars$3.32+2.2%N/A-39.1%$20.08M$125.48M-2.39290BCTXBriacell Therap1.8852 of 5 stars$2.89-0.7%$32.00+1,007.3%-94.4%$19.72MN/A-0.358LGVNLongeveron3.031 of 5 stars$1.29-1.5%$8.67+571.8%-58.5%$19.56M$2.39M-0.2120JATTJATT AcquisitionN/A$1.13+0.9%N/A-64.8%$19.49MN/A0.003High Trading VolumeBLRXBioLineRx2.6497 of 5 stars$4.32-3.8%$26.00+501.9%-85.9%$19.14M$22.34M-0.4940CINGCingulate2.954 of 5 stars$4.42+3.3%$26.00+488.2%+1,276.5%$18.17MN/A-0.5220MRKRMarker Therapeutics4.3216 of 5 stars$1.57-1.9%$13.17+738.6%-72.6%$18.10M$6.59M-1.1860Gap UpTrading HaltedBIVIBioVie1.0695 of 5 stars$8.10-15.6%N/A+62.6%$17.83MN/A-1.0210Positive NewsQTTBQ32 Bio2.7077 of 5 stars$1.36-5.6%$12.17+794.6%-89.6%$17.57M$1.16M-0.2839 Related Companies and Tools Related Companies MIRA Pharmaceuticals Competitors Natural Alternatives International Competitors Briacell Therap Competitors Longeveron Competitors JATT Acquisition Competitors BioLineRx Competitors Cingulate Competitors Marker Therapeutics Competitors BioVie Competitors Q32 Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts